Delving into the Latest Updates on Bristol-Myers Squibb SRL with Synapse

An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial

The study's hypothesis is that using Nivolumab as early switch maintenance, after 4-6 cycles of standard first-line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.

开始日期2017-09-25

申办/合作机构

Bristol-Myers Squibb SRL

[+3]

CTR20132365 / Recruiting临床2期

400mg伊马替尼治疗3个月未获得最佳响应的慢粒白血病患者中达沙替尼vs伊马替尼治疗的开放标记、随机2B期研究

本研究的主要目的是比较一线伊马替尼治疗未获得最佳反应（BCR-ABL＞10%IS），在第3个月被随机分配接受达沙替尼100mgQD或任何剂量伊马替尼治疗的患者中，一线伊马替尼第1天治疗后的12个月MMR率.

开始日期2014-05-08

申办/合作机构

百时美施贵宝（中国）投资有限公司

[+3]

100 项与 Bristol-Myers Squibb SRL 相关的临床结果

登录后查看更多信息

0 项与 Bristol-Myers Squibb SRL 相关的专利（医药）

登录后查看更多信息

1

项与 Bristol-Myers Squibb SRL 相关的文献（医药）

ClinicoEconomics and Outcomes Research

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Article

作者: Di Giambenedetto, Simona ; Restelli, Umberto ; Fabbiani, Massimiliano ; Nappi, Carmela ; Croce, Davide

100 项与 Bristol-Myers Squibb SRL 相关的药物交易

登录后查看更多信息

100 项与 Bristol-Myers Squibb SRL 相关的转化医学

登录后查看更多信息